DEF 14A: Catheter Precision Seeks Stockholder Approval for Warrant Exercise, Share Increase, and Equity Plan Amendment

Catheter Precision is holding a special meeting to seek stockholder approval for several key proposals, including the issuance of shares upon warrant exercise, an increase in authorized shares, and an amendment to the equity incentive plan.

Summary

• Catheter Precision is convening a special stockholder meeting on January 13, 2025, to vote on five proposals.
• The first proposal seeks approval for the issuance of up to 10,695,962 shares of common stock upon the exercise of Series K warrants.
• The second proposal requests an increase in the number of authorized common shares from 30 million to 60 million.
• The third proposal aims to add 1.5 million shares to the 2023 Equity Incentive Plan.
• The fourth proposal seeks ratification of WithumSmith+Brown, PC as the company's independent auditor for the fiscal year ending December 31, 2025.
• The fifth proposal is to approve the adjournment of the meeting if necessary to solicit more votes.
• The company had 8,004,633 shares of common stock outstanding as of November 18, 2024, held by 78 record holders.
• Stockholders can vote by proxy via the internet, telephone, or mail, or attend the meeting via webcast after registering by January 12, 2025.

Sentiment

Score: 4

Explanation: The document highlights the company's need for capital and the potential for significant dilution, which are negative factors. While the company is taking steps to raise funds and incentivize employees, the overall tone suggests financial challenges and potential risks for investors.

Positives

• The warrant exercise proposal, if approved, could provide the company with additional capital.
• Increasing the authorized shares provides flexibility for future financing and strategic opportunities.
• Adding shares to the equity incentive plan will help attract and retain key talent.
• Ratifying the auditor ensures continued financial oversight.
• The company has taken steps to reduce the exercise price of existing warrants to encourage their exercise.

Negatives

• The issuance of new shares upon warrant exercise will cause dilution to existing stockholders.
• Failure to approve the proposals could hinder the company's ability to raise capital and execute its business strategy.
• The company may need to hold additional meetings every 90 days to seek approval for the warrant exercise if it is not approved at this meeting.
• The company has a history of changing auditors.

Risks

• Failure to obtain stockholder approval for the warrant exercise could discourage future investors.
• The company may have difficulty finding alternative sources of capital if the proposals are not approved.
• The company may need to significantly curtail its operations or even file for bankruptcy if it cannot raise additional capital.
• The issuance of a large number of shares could significantly dilute the value of existing shares.
• The company is obligated to file a registration statement for the resale of shares underlying the Series K Warrants and cause it to become effective within a specific timeframe.

Future Outlook

The company intends to use the net proceeds from any Series K Warrant exercises to advance the development and commercialization of its electrophysiology technologies and for general corporate purposes. The company expects to require raising additional capital to fund its operations, which may involve the issuance of common stock.

Management Comments

• David A. Jenkins, Executive Chairman of the Board, stated that the board believes the Inducement Offer and the proposals are in the best interests of the company and its stockholders.
• The board believes it is in the best interest of the Company and its shareholders to increase the number of authorized shares of common stock to provide the Company with flexibility to issue shares of common stock for general corporate purposes.

Industry Context

The proposals are related to the company's need for capital and its desire to incentivize employees, which are common themes in the biotechnology and medical device industries. The company's need to raise capital is likely due to the high costs associated with research, development, and commercialization of medical technologies.

Comparison to Industry Standards

• The company's need to increase authorized shares is not uncommon for companies in the growth phase, especially in capital-intensive industries like medical devices.
• The use of equity incentive plans is a standard practice to attract and retain talent in competitive markets.
• The company's reliance on warrant exercises for funding is a common strategy for smaller companies, but it can lead to significant dilution for existing shareholders.
• The company's decision to reprice warrants to encourage exercise is a tactic used by companies to raise capital quickly, but it can be seen as a sign of financial distress.
• The company's engagement of Alliance Advisors, LLC for proxy solicitation is a standard practice for companies seeking to ensure sufficient stockholder participation in important votes.

Stakeholder Impact

• Shareholders will be impacted by potential dilution from the issuance of new shares.
• Employees may benefit from the increased availability of equity compensation.
• The company's ability to continue operations and develop its technologies depends on the outcome of the proposals.
• Creditors may be impacted by the company's ability to raise capital and meet its obligations.

Next Steps

• Stockholders will vote on the proposals at the special meeting on January 13, 2025.
• The company will file a registration statement for the resale of shares underlying the Series K Warrants.
• The company will continue to seek ways to raise capital to fund its operations.

Key Dates

Keywords

warrant exercise, authorized shares, equity incentive plan, stockholder meeting, proxy statement, common stock, auditor ratification, dilution, capital raise, WithumSmith+Brown